Biocon’s Q3 FY 2019-20 Results Conference Call
At 9.00 am IST on January 24, 2020

Biocon Limited (BSE code: 532523, NSE Id: BIOCON) will announce results for the third quarter of FY 2019-20, ended December 31, 2019 on January 23, 2020. Following the announcement, the management of Biocon Limited will host an earnings call to discuss the Company’s performance on January 24, 2020.

Details of the conference call are as under:

<table>
<thead>
<tr>
<th>Date:</th>
<th>Friday, January 24, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time:</td>
<td>9.00 am IST</td>
</tr>
<tr>
<td>Duration:</td>
<td>60 minutes</td>
</tr>
</tbody>
</table>

Dial-in Numbers:

Participation are encouraged to dial in 10 minutes prior to the call start to avoid hold times at the last minute. If you reach on operator during the dial in process please inform the operator that you would like to join "Biocon Ltd. Q3 FY20 Earnings Conference Call”

<table>
<thead>
<tr>
<th>Universal Access numbers</th>
<th>+91 22 6280 1151</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+91 22 7115 8052</td>
</tr>
<tr>
<td>Local Access (All India)</td>
<td>+91 70456 71221</td>
</tr>
<tr>
<td>International Local Access Numbers</td>
<td>USA: +1 323 386 8721</td>
</tr>
<tr>
<td></td>
<td>UK: +44 20 3478 5524</td>
</tr>
<tr>
<td></td>
<td>Singapore: +65 3157 5746</td>
</tr>
<tr>
<td></td>
<td>Hong Kong: +852 3018 6877</td>
</tr>
</tbody>
</table>

Pre-Registration Facility

- Step 1: Pre-register [here](#). You will receive an email confirmation with the call details on the registered email address
- Step 2: Dial into the call on the Conference Call date, you are directly connected to the call

Replay Facility

The replay will be available 60 minutes after the earnings call ends.
Dial in number: +91 22 7194 5757
Playback Code: 03055
Replay available till January 31, 2020

Transcript

Will be made available after a few days on the Company’s website

Please note: This call is not open to the members of the media (print/online)
About Biocon

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. Biocon has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the U.S. and Europe. It is a leading global player for APIs including statins, immunosuppressants and specialty molecules. It also has a pipeline of promising novel assets in immunotherapy under development. Biocon Biologics is a subsidiary of Biocon Ltd. It is uniquely positioned as a fully integrated ‘pure play’ biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions. The Company has a large portfolio of biosimilars under global clinical development with three of these commercialized in developed markets like EU, Australia, U.S. and Japan. Biocon is committed to pursue the path of innovation to develop products that have the potential to benefit a billion lives. For more information, visit www.biocon.com or follow Biocon on Twitter: @bioconlimited

Contact:

For further information please contact:

Saurabh Paliwal
Investor Relations – Biocon Limited
☎ +91 80 6775 2040
✉: investor.relations@biocon.com

Diwakar Pingle
Christensen Investor Relations
☎ +91 22 4215 0210
✉: dpingle@ChristensenIR.com

Safe Harbor: Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management’s current assumptions and expectations concerning future developments and their potential effects upon Biocon and its subsidiaries/associates. There can be no assurance that future developments affecting Biocon and its subsidiaries/associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties that may cause actual results to differ, possibly materially, from those contemplated by such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, our directors, nor any of our subsidiaries/ associates assume any obligation to update or otherwise revise any statements reflecting circumstances arising after conclusion of the conference call to reflect the occurrence of underlying events, even if the underlying assumptions and expectations do not come to fruition.